GLP-1 RAs require integrated lifestyle support for durable cardiometabolic health, argue experts

Obesity and type 2 diabetes represent significant global health challenges, driving substantial cardiometabolic disease burden. Recent advancements in pharmacotherapy, particularly with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide, have revolutionized management by inducing significant weight loss and improving glycemic control and cardiovascular and renal risk. However, a critical gap remains in understanding how these powerful medications integrate with foundational lifestyle interventions. Current standard-of-care often struggles with long-term adherence to lifestyle changes, and the role of pharmacotherapy in sustaining these behaviors or addressing broader health determinants is not fully defined.

This article, a perspective piece, advances a guiding principle for contemporary cardiometabolic care: 'lifestyle first and lifestyle always, but not lifestyle only.' The authors synthesize current understanding of GLP-1 RAs in managing obesity and type 2 diabetes, critically evaluating the limitations of pharmacotherapy alone. They propose integrated, interprofessional models that combine pharmacologic and lifestyle strategies, supported by policy and systems change, as the emerging standard for long-term health. The methodology involves a conceptual analysis and synthesis of existing clinical evidence and societal challenges related to cardiometabolic disease management, aiming to reframe the role of GLP-1 RAs within a holistic health paradigm.

The authors contend that while GLP-1 RAs have reshaped clinical practice and reinforced the recognition of obesity as a biologically mediated disease, pharmacotherapy alone cannot resolve the complex behavioral, physiological, and social drivers of cardiometabolic risk. They highlight that discontinuation of GLP-1 RAs without structured lifestyle support commonly results in weight regain, underscoring the medications' role as a tool rather than a complete solution. Furthermore, medication does not inherently address critical aspects of health such as sarcopenia, physical deconditioning, sleep quality, stress management, psychosocial determinants, or social connection. The paper emphasizes that lifestyle behaviors—including high-quality nutrition, regular physical activity (especially resistance training), restorative sleep, stress management, social connectedness, and a sense of purpose—constitute the physiological and behavioral foundation for durable health gains.

GLP-1 RAs are therefore positioned not as substitutes for lifestyle change, but as catalysts that create metabolic and psychological conditions favorable to adopting and sustaining healthy behaviors.

This perspective advocates for integrated, interprofessional models that combine pharmacologic and lifestyle strategies, supported by policy and systems change, as the emerging standard for long-term cardiometabolic health.